Ishjas Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 28-12-2024
- Paid Up Capital ₹ 0.10 M
as on 28-12-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.78 Cr
as on 28-12-2024
- Satisfied Charges ₹ 1.50 M
as on 28-12-2024
- Revenue 20.88%
(FY 2020)
- Profit 95.92%
(FY 2020)
- Ebitda -48.42%
(FY 2020)
- Net Worth 35.23%
(FY 2020)
- Total Assets 33.78%
(FY 2020)
About Ishjas Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.78 Cr. The company has closed loans amounting to ₹1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Jitender Singh, Balwinder Kaur, and Devender Singh serve as directors at the Company.
- CIN/LLPIN
U24100DL2007PTC164626
- Company No.
164626
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ishjas Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitender Singh  | Managing Director | 12-Jun-2007 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Balwinder Kaur | Director | 01-Aug-2017 | Current |
| Devender Singh | Director | 26-Oct-2017 | Current |
Financial Performance of Ishjas Pharma.
Ishjas Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 20.88% increase. The company also saw a substantial improvement in profitability, with a 95.92% increase in profit. The company's net worth Soared by an impressive increase of 35.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ishjas Pharma?
In 2019, Ishjas Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Jul 2024 | ₹6.20 M | Open |
Others Creation Date: 19 Jan 2021 | ₹2.00 Cr | Open |
Syndicate Bank Creation Date: 22 Dec 2017 | ₹1.56 M | Open |
How Many Employees Work at Ishjas Pharma?
Ishjas Pharma has a workforce of 12 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ishjas Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ishjas Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
